ACURX PHARMACEUTICALS LLC

NASDAQ: ACXP (Acurx Pharmaceuticals, Inc.)

Last update: 2 hours ago

0.500

0.01 (2.35%)

Previous Close 0.489
Open 0.481
Volume 1,652,996
Avg. Volume (3M) 6,383,403
Market Cap 11,740,800
Price / Book 4.90
52 Weeks Range
0.300 (-40%) — 3.33 (565%)
Earnings Date 7 Aug 2025 - 11 Aug 2025
Diluted EPS (TTM) -0.700
Current Ratio (MRQ) 1.93
Operating Cash Flow (TTM) -9.37 M
Levered Free Cash Flow (TTM) -4.87 M
Return on Assets (TTM) -106.68%
Return on Equity (TTM) -285.79%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Acurx Pharmaceuticals, Inc. Bearish Bearish

AIStockmoo Score

0.6
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators 0.5
Average 0.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ACXP 12 M - - 4.90
MRNA 12 B - - 1.17
CGON 2 B - - 2.81
CVAC 1 B - 5.77 1.61
VIR 731 M - - 0.720
ZVRA 616 M - - 12.54

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 10.95%
% Held by Institutions 17.99%

Ownership

Name Date Shares Held
Prospect Financial Services Llc 31 Mar 2025 366,576
Nbc Securities, Inc. 31 Mar 2025 30,000
Semmax Financial Advisors Inc. 31 Mar 2025 5,640
52 Weeks Range
0.300 (-40%) — 3.33 (565%)
Median 8.00 (1,500.00%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 15 May 2025 8.00 (1,500.00%) Buy 0.373
Date Type Details
27 Jun 2025 Announcement New to The Street Announces the Broadcast of Show Number 675 This Saturday at 6:30 PM EST on Bloomberg Television Featuring: FLOKI, BioVie (NASDAQ: BIVI), Arrive AI ($ARAI), Health In Tech (NASDAQ HIT), and Commercialville T.V.
17 Jun 2025 Announcement Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
17 Jun 2025 Announcement /C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
09 Jun 2025 Announcement New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
09 Jun 2025 Announcement Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
13 May 2025 Announcement Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
30 Apr 2025 Announcement Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
28 Apr 2025 Announcement Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
17 Apr 2025 Announcement Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
16 Apr 2025 Announcement New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
12 Apr 2025 Announcement New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Pres...
11 Apr 2025 Announcement New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Pre...
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria